10 results about "Drug usage" patented technology

The present application relates to the technical field of knowledge graph, in particular to a multi-task hepatitis B drug screening method and system based on knowledge graph assistance, comprising the following steps: based on hepatitis B virus genotype sequence data recorded over time, patient drug use records and drug sensitivity. In the present application, multi-dimensional dynamic time series data such as virus genotype sequence data, patient drug use records and drug sensitivity are integrated, the interaction events between entities are marked by time stamp, the dynamic characteristics such as virus variation track and drug efficacy change are embedded in the graph node attributes, so that the knowledge representation can reflect the time dependence in the real scene. Based on biological pathway annotation information and protein interaction data, the hyperedge connection multi-entity set is defined, the limitation of traditional knowledge graph which only supports binary relationship is expanded, the drug combination and multi-target synergistic mechanism are explicitly modeled, and the misjudgment of combination effect caused by the simplification of interaction relationship is avoided.

The present invention relates to a gene construct and use thereof. The gene construct is used for inhibiting the excessive excitation of neurons caused by excessive use or abuse of addictive substances. The gene construct comprises a neuronal inhibitory protein-coding gene and a promoter operably linked to the neuronal inhibitory protein-coding gene. The gene construct exhibits significant advantages in terms of precise targeting, closed-loop regulation, retention of natural reward responses, reduction of side effects, and improvement of safety, as well as potential long-acting properties and sustainability. This strategy provides a novel idea and method for the treatment of drug use disorders, and is expected to become an important breakthrough in the field of drug use disorders in the future.

This invention relates to the application of PGG in the preparation of drugs for treating acute leukemia, belonging to the field of biomedical technology. To address the problems of narrow application range and easy development of drug resistance in existing acute leukemia treatments, this invention provides the application of PGG in the preparation of drugs for treating acute leukemia. Experiments have shown that PGG can inhibit the viability, proliferation, and colony formation of human acute myeloid leukemia cells (MOLM-13) and human acute lymphoblastic leukemia cells (Jurkat), and induce their apoptosis. In animal models, intraperitoneal injection of PGG can prolong the survival days of mice with acute leukemia and reduce the infiltration of leukemia cells in the liver, spleen, and bone marrow tissues. In this invention, PGG directly inhibits the viability of acute leukemia cells and can simultaneously inhibit AML and ALL, without relying on specific gene mutations, resulting in a lower risk of drug resistance, more flexible clinical use, and broader patient coverage, showing promising clinical application prospects.

The present description relates to a method for treating a patient having a mood disorder, comprising administering to a subject in need a pharmaceutical composition comprising a base compound consisting substantially of N-ethyl-2-(5-fluoro-1H-indol-3-yl)-N-methylethan-1-amine or a pharmaceutically acceptable salt thereof in a specified dosage regimen.

A system and method for managing medication titration using real-time walking and balance data collected from mobile electronic devices are disclosed. Smartphone sensors, including accelerometers and gyroscopes, capture mobility metrics such as gait speed, stride characteristics, postural stability, and fall risk. The mobility data is integrated with additional physiological metrics and a patient's electronic medical records. Analytical algorithms, including machine-learning models, evaluate changes in mobility to identify correlations between medication usage and functional performance. Based on detected changes, the system generates alerts and recommendations to assist healthcare providers in adjusting medication dosages. The invention supports proactive and personalized medication management, particularly for medications that affect balance or fall risk, and improves patient safety by enabling data-driven clinical decision-making using real-world mobility insights.

The application discloses application of methylphenidate in preparation of a post-traumatic stress disorder (PTSD) psychotherapy enhancer. The methylphenidate is used in the introduction period of PTSD psychotherapy, and can improve the treatment effect of core symptoms of PTSD, including intrusive symptoms, avoidance symptoms, high vigilance symptoms, negative thinking and emotion. The application uses single methylphenidate to disturb patients into an unstable state, adjusts a time window for reconsolidation of trauma memory, and strengthens the decline of trauma memory and the update of healing memory in the time window. Furthermore, compared with daily medication, single medication has clinical significance of reducing the psychological burden and economic burden of patients on drug use. Therefore, the application uses single methylphenidate in the introduction period of PTSD psychotherapy.

The application relates to the technical field of pharmaceutical preparations, and discloses an agomelatine inhalant as well as a preparation method and application thereof. The agomelatine inhalant provided by the application comprises agomelatine or a pharmaceutically acceptable salt thereof in a form capable of being inhaled or capable of being changed into a form capable of being inhaled after being excited. From the aspect of synergism, the inhalant can avoid first-pass metabolism by changing a drug administration route, significantly improve bioavailability, and realize rapid effect by directly entering blood from the lung; from the aspect of attenuation, the inhalant can greatly reduce a drug usage amount to achieve a same treatment effect as a tablet, significantly reduce occurrence of drug toxic and side reactions, and significantly reduce liver toxicity by avoiding liver metabolism.

The present invention relates to an automated packaging machine for pharmaceuticals and a method of operating the same. The method comprises: receiving, at an electronic processor of a pharmacy management system, a prescription to be filled by the pharmacy management system; placing one or more pill cartridges comprising medications listed on the prescription at the automated packaging machine; using the automated packaging machine to separate the medications in the one or more pill cartridges for individually dispensing the medications; verifying each medication using the automated packaging machine as the medications are in the one or more pill cartridges or as the medications are dispensed from the one or more pill cartridges; capturing an image of each medication as the medications are dispensed from the one or more pill cartridges; packaging the medications dispensed from the one or more pill cartridges into a package using a packaging unit of the automated packaging machine; and verifying that the medications are correctly packaged using the automated packaging machine.

This invention discloses a method, device, equipment, and medium for dynamic management of controlled substances. The method includes: determining the drug information, dispensing information, and patient identification information corresponding to the controlled substances to be dispensed; allowing the dispensing of the controlled substances after verification based on the drug information, dispensing information, and patient identification information; determining the drug usage information, drug retrieval information, and drug traceability information of the controlled substances to be dispensed; verifying the consistency of use of the controlled substances to be dispensed based on the drug information, dispensing information, patient identification information, drug usage information, drug retrieval information, and drug traceability information; and determining the management log of the controlled substances to be dispensed based on the drug information, dispensing information, patient identification information, dispensing compliance verification results, and usage consistency verification results. This achieves full traceability of drugs from dispensing to use and retrieval, meeting the stringent requirements of controlled substance management regulations.